Philippa Gee - Wealth Management - Shropshire
  • Home
  • About
  • Approach
  • People
  • Press
  • Contact

10/11/17 Philippa comments in The Telegraph

Posted on February 20, 2018 by Philippa Gee

http://www.telegraph.co.uk/investing/funds/biotech-stocks-560pc-decade-play-sector/

 

This entry was posted in Blog. Bookmark the permalink.

Post navigation

23/10/17 Philippa shortlisted as finalist for Investment Woman of the Year
22/11/17 Philippa comments in The Independent

Recent Posts

  • 26/4/19 Philippa comments in The Times
  • 20/3/19 Philippa comments in The Times
  • 27/3/19 Philippa comments in The Times
  • 13/2/19 – Philippa comments in Money Observer
  • 16/11/18 – Philippa comments in The Times

Archives

  • May 2019
  • February 2018
  • May 2017
  • February 2017
  • April 2016
  • March 2015
  • September 2014
  • July 2014
  • May 2014
  • February 2014
  • March 2013
  • November 2012
  • October 2012
  • July 2012
  • April 2012
  • February 2012
  • January 2012
  • September 2011

Categories

  • Blog

Contact

Philippa Gee Wealth Management Ltd
8 High Street
Church Stretton
Shropshire
SY6 6BU

Telephone 01694 722222
[email protected]

Registered in England & Wales No: 07221964

Legal

Philippa Gee Wealth Management Ltd is authorised and regulated by the Financial Conduct Authority.

The Financial Ombudsman Service is available to sort out individual complaints that clients and financial services businesses aren't able to resolve themselves. To contact the Financial Ombudsman Service please visit www.financial-ombudsman.org.uk

Privacy | Cookies

Connect

  • Follow me on LinkedIn
  • Follow me on Twitter

We ask all our clients to please take care to note that past performance is no guide to what might happen in the future, and that the value of investments and the income received from them may fall as well as rise. You must be aware that your home may be repossessed if you do not keep up repayments on your mortgage. The guidance and/or advice contained within the website is subject to the UK regulatory regime and is therefore primarily targeted at customers in the UK.